William R Burns

List of Publications by Year
in descending order

37 papers	1,650 citations	430874 18 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	2400 citing authors

#	Article	IF	Citations
1	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 401-414.	1.5	11
2	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Surgery, 2022, 171, 1379-1387.	1.9	7
3	ASO Author Reflections: Surgeons Adding Valueâ€"Are Synoptic Operative Reports a Step Forward in Cancer Care?. Annals of Surgical Oncology, 2022, , 1.	1.5	1
4	ASO Visual Abstract: Technical Standards for Cancer Surgeryâ€"Improving Patient Care through Synoptic Operative Reporting. Annals of Surgical Oncology, 2022, , 1.	1.5	0
5	Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. World Journal of Surgery, 2022, 46, 667-677.	1.6	5
6	Limited English Proficiency and Clinical Outcomes After Hospital-Based Care in English-Speaking Countries: a Systematic Review. Journal of General Internal Medicine, 2022, 37, 2050-2061.	2.6	20
7	Technical Standards for Cancer Surgery: Improving Patient Care through Synoptic Operative Reporting. Annals of Surgical Oncology, 2022, 29, 6526-6533.	1.5	10
8	Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Clinical Cancer Research, 2022, 28, 3296-3307.	7.0	27
9	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. JCO Precision Oncology, 2022, , .	3.0	1
10	Perioperative Outcomes of Robotic Pancreaticoduodenectomy: a Propensity-Matched Analysis to Open and Laparoscopic Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2021, 25, 1795-1804.	1.7	43
11	Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin. Journal of Surgical Oncology, 2021, 123, 416-424.	1.7	12
12	Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the â€œhalo signâ€•and â€œstring signâ€• Surgery, 2021, 169, 1026-1031.	1.9	37
13	Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. Hpb, 2021, 23, 575-586.	0.3	10
14	An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). Annals of Surgical Oncology, 2021, 28, 3125-3134.	1.5	28
15	Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Journal of the American College of Surgeons, 2021, 232, 405-413.	0.5	39
16	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Cancer Letters, 2021, 497, 221-228.	7.2	10
17	Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. Hpb, 2021, 23, 468-474.	0.3	6
18	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight, 2021, 6, .	5.0	10

#	Article	IF	Citations
19	Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. World Journal of Surgery, 2021, 45, 3157-3164.	1.6	1
20	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer, 2021, 2, 891-903.	13.2	147
21	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 714-715.	1.5	1
22	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 2021, 10, 2001159.	4.6	10
23	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Letters, 2020, 493, 245-253.	7.2	18
24	Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Surgery, 2020, 168, 1048-1055.	1.9	22
25	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	4.2	61
26	Completion Lymph Node Dissection or Radiation Therapy for Sentinel Node Metastasis in Merkel Cell Carcinoma. Annals of Surgical Oncology, 2019, 26, 386-394.	1.5	37
27	Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Annals of Surgical Oncology, 2017, 24, 2023-2030.	1.5	230
28	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. , 2014, 2, 25.		112
29	Cell Surface Lactate Receptor GPR81 Is Crucial for Cancer Cell Survival. Cancer Research, 2014, 74, 5301-5310.	0.9	203
30	Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update. Current Treatment Options in Oncology, 2012, 13, 24-34.	3.0	85
31	The position of the AUG start codon in MFGâ€based Î³â€retroviral vectors has a dramatic effect on translationâ€dependent protein expression. Journal of Gene Medicine, 2011, 13, 478-486.	2.8	3
32	Differentiated Thyroid Cancer. Seminars in Oncology, 2010, 37, 557-566.	2.2	107
33	Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase. Journal of Immunology, 2010, 184, 5988-5998.	0.8	75
34	A High Molecular Weight Melanoma-Associated Antigenâ€“Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas. Cancer Research, 2010, 70, 3027-3033.	0.9	70
35	Lack of specific Î³-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood, 2009, 114, 2888-2899.	1.4	60
36	Recruitment of CXCR3+ and CCR5+ T Cells and Production of Interferon-Î³-Inducible Chemokines in Rejecting Human Arteries. American Journal of Transplantation, 2005, 5, 1226-1236.	4.7	67

#	Article	IF	Citations
37	Interferonâ€Î³ plays a nonredundant role in mediating Tâ€cellâ€dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB Journal, 2004, 18, 606-608.	0.5	64